CST, 28275SF, TIGIT (Tiragolumab Biosimilar) Human Monoclonal Antibody

Monoclonal Antibody for studying TIGIT. Validated for Neutralizing. Highly specific and rigorously validated in-house, TIGIT (Tiragolumab Biosimilar) Human Monoclonal Antibody (CST #28275) is ready to ship. Product Usage Information This product is intended for research use only (RUO). Optimal dilutions/concentrations should be determined by the end user. Formulation Supplied in 1X PBS, BSA and Azide Free. Storage Store at -20°C. This product will freeze at -20°C so it is recommended to aliquot into single-use vials to avoid multiple freeze/thaw cycles. A slight precipitate may be present and can be dissolved by gently vortexing. This will not interfere with antibody performance. Specificity / Sensitivity TIGIT (Tiragolumab Biosimilar) Human Monoclonal Antibody was confirmed to bind to its intended target protein TIGIT using flow cytometry. Species Reactivity: Human Source / Purification TIGIT (Tiragolumab Biosimilar) Human mAb is produced at Cell Signaling Technology. Tiragolumab is an antibody directed against the extracellular region of human TIGIT. Background T-cell immunoreceptor with Ig and ITIM domains (TIGIT), also known as VSIG9, VSTM3, and WUCAM, is a member of the poliovirus receptor family of immunoglobulin proteins (1-3). TIGIT is expressed at low levels on subsets of T cells and NK cells, and is upregulated at the protein level following activation of these cells (1-4). TIGIT marks exhausted T cells in the tumor microenvironment (5) and during human immunodeficiency virus (HIV) infection (6). Research has shown TIGIT interacts with several receptors expressed on antigen presenting cells, such as dendritic cells and macrophages, as well as tumor cells and cells of the microenvironment. TIGIT binds with high affinity to PVR/CD155, and with low affinity to Nectin-2/CD112 and Nectin-3/CD113 (2,4,7). Upon binding to its ligands, TIGIT suppresses T cell activation, and inhibits T and NK cell cytotoxicity. This inhibition can be blocked using monoclonal antibodies directed at the extracellular domain of TIGIT, resulting in rejuvenated antigen-specific CD8 T cell responses in tumors and during HIV infection (5,6,8). Three potential isoforms of TIGIT have been computationally mapped (9). Alternate Names FLJ39873; T cell immunoreceptor with Ig and ITIM domains; T-cell immunoreceptor with Ig and ITIM domains; TIGIT; V-set and immunoglobulin domain containing 9; V-set and immunoglobulin domain-containing protein 9; V-set and transmembrane domain containing 3; V-set and transmembrane domain-containing protein 3; VSIG9; VSIG9, VSTM3; VSTM3; Washington University cell adhesion molecule; WUCAM Specification REACTIVITY: H SENSITIVITY: Endogenous Source/Isotype: Human IgG1 kappa